Welcome to our dedicated page for Tcr2 Therapeutics news (Ticker: TCRR), a resource for investors and traders seeking the latest updates and insights on Tcr2 Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tcr2 Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tcr2 Therapeutics's position in the market.
On September 29, 2020, TCR2 Therapeutics Inc. (Nasdaq: TCRR) announced its management's participation in a fireside chat at the Jefferies Cell Therapy Virtual Summit on October 5, 2020, at 2:00 PM ET. This event will utilize a virtual platform, with a live webcast available on the Company’s Investors page and an archived replay accessible for at least 30 days post-presentation.
TCR2 Therapeutics focuses on innovative T cell therapies for various cancers, with ongoing Phase 1/2 clinical trials for its lead candidates, TC-210 and TC-110.
TCR2 Therapeutics (Nasdaq: TCRR), a clinical-stage immunotherapy company, announced that CFO Ian Somaiya will present updates at two virtual conferences this September. The presentations include:
- H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 12:30 PM ET
- Cantor Global Healthcare Conference on September 17, 2020, at 9:20 AM ET
Investors can access live webcasts on the company’s website, with archived replays available for 30 days. TCR2 develops novel T cell therapies targeting various cancers.
TCR2 Therapeutics (Nasdaq: TCRR) reported strong progress in its clinical trials for TC-210 and TC-110 amid the pandemic. TC-210 has shown tumor regression in five patients, with one confirmed partial response improving from 42% to 75%. The company raised $142.6 million in gross proceeds during a secondary offering, extending its cash runway into 2023. The financial results for Q2 2020 showed a net loss of $16.2 million, up from $11.1 million in Q2 2019, primarily due to increased research and development expenses.
TCR2 Therapeutics Inc. (Nasdaq: TCRR) announced the pricing of an underwritten public offering of 8,000,000 shares at $15.50 per share, with gross proceeds expected to reach $124 million. The underwriters have a 30-day option to purchase an additional 1,200,000 shares. The funds will be used to advance clinical programs and for general corporate purposes. The offering is anticipated to close around July 31, 2020, pending customary conditions.
TCR2 Therapeutics Inc. (Nasdaq: TCRR) announced a public offering of 6,000,000 shares of common stock, with a 30-day option for underwriters to buy an additional 900,000 shares. The offering aims to support the advancement of TCR2's clinical programs and for general corporate purposes. The offering will be conducted under a shelf registration statement effective since April 28, 2020. Jefferies, SVB Leerink, Piper Sandler, and BMO Capital Markets are managing the offering. Market conditions may impact completion and terms of the offering.
TCR2 Therapeutics (Nasdaq: TCRR) reported encouraging interim results from the Phase 1 portion of the TC-210 clinical trial for mesothelin-expressing solid tumors. Tumor regression was observed in all five patients treated, with two unconfirmed partial responses and two with stable disease over six months. The safety profile was deemed manageable, with only one patient exhibiting significant toxicity. Translational data indicated T cell expansion and activation, suggesting potential efficacy. Further studies are ongoing to define the recommended Phase 2 dose.
On June 17, 2020, TCR2 Therapeutics (Nasdaq: TCRR) announced that CFO Ian Somaiya will present updates on the company's progress at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 1:00 PM ET via a virtual platform. A live webcast will be available on the company's investor relations page, with an archived version accessible for 30 days post-event. TCR2 focuses on novel T cell therapies for cancer patients, featuring TRuC®-T cells that exhibit superior anti-tumor activity in clinical trials.
TCR2 Therapeutics announced Q1 2020 financial results and provided a corporate update. The company has a cash position of $141M, sufficient for operations into 2022. Key developments include the orphan drug designation granted to TC-110 for treating acute lymphoblastic leukemia and the initiation of clinical trials for TC-210 and TC-110. The company also nominated a new product candidate targeting CD70 and appointed two new board members, enhancing its leadership.
Net loss for Q1 2020 was $15.5M, up from $9.9M in Q1 2019, driven largely by increased R&D expenses.
Summary not available.